Genmab A/S (NASDAQ:GMAB) on Monday said it will discontinue further clinical development of acasunlimab. The decision was made as part of Genmab’s strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive…
Continue reading...